Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280521732> ?p ?o ?g. }
- W4280521732 endingPage "425" @default.
- W4280521732 startingPage "405" @default.
- W4280521732 abstract "Introduction Triple-negative breast cancer (TNBC) is the most fatal molecular subtype of breast cancer because of its aggressiveness and resistance to chemotherapy. FDA-approved therapies for TNBC are limited to poly(ADP-ribose) polymerase inhibitors, immune checkpoint inhibitors, and trophoblast cell surface antigen 2-targeted antibody-drug conjugate. Therefore, developing a novel effective targeted therapy for TNBC is an urgent unmet need.Areas covered In this narrative review, we discuss emerging targets for TNBC treatment discovered in early translational studies. We focus on cancer cell membrane molecules, hyperactive intracellular signaling pathways, and the tumor microenvironment (TME) based on their druggability, therapeutic potency, specificity to TNBC, and application in immunotherapy.Expert opinion The significant challenges in the identification and validation of TNBC-associated targets are 1) application of appropriate genetic, molecular, and immunological approaches for modulating the target, 2) establishment of a proper mouse model that accurately represents the human immune TME, 3) TNBC molecular heterogeneity, and 4) failure translation of preclinical findings to clinical practice. To overcome those difficulties, future research needs to apply novel technology, such as single-cell RNA sequencing, thermostable group II intron reverse transcriptase sequencing, and humanized mouse models. Further, combination treatment targeting multiple pathways in both the TNBC tumor and its TME is essential for effective disease control." @default.
- W4280521732 created "2022-05-22" @default.
- W4280521732 creator A5018426062 @default.
- W4280521732 creator A5025672158 @default.
- W4280521732 creator A5031867067 @default.
- W4280521732 creator A5072948474 @default.
- W4280521732 creator A5088814426 @default.
- W4280521732 date "2022-05-04" @default.
- W4280521732 modified "2023-09-27" @default.
- W4280521732 title "Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape" @default.
- W4280521732 cites W1486227004 @default.
- W4280521732 cites W1607681758 @default.
- W4280521732 cites W1804398254 @default.
- W4280521732 cites W1807390963 @default.
- W4280521732 cites W1933761723 @default.
- W4280521732 cites W1963083447 @default.
- W4280521732 cites W1985566789 @default.
- W4280521732 cites W1995224853 @default.
- W4280521732 cites W1997754945 @default.
- W4280521732 cites W2004152105 @default.
- W4280521732 cites W2006122819 @default.
- W4280521732 cites W2007158513 @default.
- W4280521732 cites W2009189697 @default.
- W4280521732 cites W2012540236 @default.
- W4280521732 cites W2013335792 @default.
- W4280521732 cites W2014200966 @default.
- W4280521732 cites W2016133753 @default.
- W4280521732 cites W2017316747 @default.
- W4280521732 cites W2026104900 @default.
- W4280521732 cites W2028438420 @default.
- W4280521732 cites W2031954417 @default.
- W4280521732 cites W2032032028 @default.
- W4280521732 cites W2033816932 @default.
- W4280521732 cites W2048321002 @default.
- W4280521732 cites W2057961799 @default.
- W4280521732 cites W2059586354 @default.
- W4280521732 cites W2077153806 @default.
- W4280521732 cites W2079068389 @default.
- W4280521732 cites W2084878128 @default.
- W4280521732 cites W2084894578 @default.
- W4280521732 cites W2093070846 @default.
- W4280521732 cites W2094530868 @default.
- W4280521732 cites W2097733789 @default.
- W4280521732 cites W2100274686 @default.
- W4280521732 cites W2104638648 @default.
- W4280521732 cites W2107975811 @default.
- W4280521732 cites W2110155621 @default.
- W4280521732 cites W2111442531 @default.
- W4280521732 cites W2115614036 @default.
- W4280521732 cites W2115736737 @default.
- W4280521732 cites W2116455112 @default.
- W4280521732 cites W2121080857 @default.
- W4280521732 cites W2123128269 @default.
- W4280521732 cites W2130378759 @default.
- W4280521732 cites W2130870648 @default.
- W4280521732 cites W2131131136 @default.
- W4280521732 cites W2132577395 @default.
- W4280521732 cites W2134134362 @default.
- W4280521732 cites W2134539328 @default.
- W4280521732 cites W2136776783 @default.
- W4280521732 cites W2138255423 @default.
- W4280521732 cites W2140617443 @default.
- W4280521732 cites W2142210663 @default.
- W4280521732 cites W2142914600 @default.
- W4280521732 cites W2147233186 @default.
- W4280521732 cites W2147601959 @default.
- W4280521732 cites W2150032631 @default.
- W4280521732 cites W2150575159 @default.
- W4280521732 cites W2153232526 @default.
- W4280521732 cites W2162868196 @default.
- W4280521732 cites W2174471079 @default.
- W4280521732 cites W2226504859 @default.
- W4280521732 cites W2257520046 @default.
- W4280521732 cites W2259128731 @default.
- W4280521732 cites W2295392443 @default.
- W4280521732 cites W2330872912 @default.
- W4280521732 cites W2341432578 @default.
- W4280521732 cites W2400903372 @default.
- W4280521732 cites W2408806914 @default.
- W4280521732 cites W2465973558 @default.
- W4280521732 cites W2482685308 @default.
- W4280521732 cites W2507131421 @default.
- W4280521732 cites W2511667040 @default.
- W4280521732 cites W2512462528 @default.
- W4280521732 cites W2521800237 @default.
- W4280521732 cites W2521845320 @default.
- W4280521732 cites W2522051371 @default.
- W4280521732 cites W2523973428 @default.
- W4280521732 cites W2537391848 @default.
- W4280521732 cites W2563661701 @default.
- W4280521732 cites W2574305039 @default.
- W4280521732 cites W2574836938 @default.
- W4280521732 cites W2585697071 @default.
- W4280521732 cites W2590374425 @default.
- W4280521732 cites W2606786998 @default.
- W4280521732 cites W2621895366 @default.
- W4280521732 cites W2737771263 @default.
- W4280521732 cites W2744829308 @default.